OncoMatch/Triple-Negative Breast Cancer (TNBC)/PD-L1 (CD274)
Triple-Negative Breast Cancer (TNBC)PD-L1 (CD274) Clinical Trials
PD-L1 combined positive score (CPS) ≥10 is required for pembrolizumab monotherapy eligibility in first-line metastatic TNBC (KEYNOTE-355); pembrolizumab plus chemotherapy is approved regardless of PD-L1 level for first-line metastatic disease. For early-stage TNBC, pembrolizumab is approved as neoadjuvant/adjuvant therapy regardless of PD-L1 status (KEYNOTE-522). Trials explore novel checkpoint combinations, LAG-3/TIM-3 inhibitors, and IO strategies across PD-L1 expression levels.
Top recruiting PD-L1 (CD274) Triple-Negative Breast Cancer (TNBC) trials
Ranked by phase and US site count. See all 15 trials matched to your profile →
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
Laura Huppert, MD, BA
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
Memorial Sloan Kettering Cancer Center
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
AstraZeneca
LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
Fudan University
All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial
Fudan University
Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS
Fundacio Clinic Barcelona